Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD8683 · 3 trials · 3 indications
Maximum FEV1 value
Trough FEV1 value
| Arm | Type | Description |
|---|---|---|
| First 50 mcg, then 200 mcg, then placebo | EXPERIMENTAL | period 1: AZD8683 50 mcg, period 2: washout, period 3: AZD8683 200 mcg, period 4:washout, period5: placebo |
| First 50 mcg, then placebo, then 200 mcg | EXPERIMENTAL | period 1: AZD8683 50 mcg, period 2: washout, period 3: placebo, period 4: washout, period5:AZD8683 200 mcg |
| First 200 mcg, then placebo, then 50 mcg | EXPERIMENTAL | period 1: AZD8683 200 mcg, period 2: washout, period 3: placebo, period 4: washout, period 5: AZD8683 50 mcg |
| First 200 mcg, then 50 mcg, then placebo | EXPERIMENTAL | period 1: AZD8683 200 mcg, period 2: washout, period 3: AZD8683 50 mcg, period 4: washout, period 5: placebo |
| First placebo, then 200 mcg, then 50 mcg | EXPERIMENTAL | period 1: placebo , period 2: washout, period 3: AZD8683 200 mcg, period 4: washout, period5: AZD8683 50 mcg |
| First placebo, then 50 mcg, then 200 mcg | EXPERIMENTAL | period 1: placebo , period 2: washout, period 3: AZD8683 50 mcg, period 4: washout, period5: AZD8683 200 mcg |
| Group 1 - 4, single ascending dose AZD 8683 | EXPERIMENTAL | Subjects will participate in 1 of 4 groups. In each group, 6 subjects will receive AZD8683 and 2 subjects will receive placebo. |
| Group 1-4 single ascending dose Placebo | PLACEBO_COMPARATOR | Subjects will participate in 1 of 4 groups. In each group, 6 subjects will receive AZD8683 and 2 subjects will receive placebo. |
| A | EXPERIMENTAL | AZD8683 |
| B | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| AZD8683, 50 mcg | DRUG | Dry powder for inhalation, single dose |
| Placebo | DRUG | Dry powder for inhalation, single dose |
| AZD8683, 200 mcg | DRUG | Dry powder for inhalation, single dose |
| AZD8683 | DRUG | Single Dose Inhaled IMP via Turbuhaler |
| Placebo to match | DRUG | Single dose Inhaled Placebo via Turbuhaler |
Inclusion Criteria: * Clinical diagnosis of COPD * Current or ex-smokers * FEV1 40 - 80% of the predicted normal value (post-bronchodilator) and post-bronchodilator FEV1/FVC \< 70% Exclusion Criteria: * Any clinically significant disease or disorder * Any clinically relevant abnormal findings at ...
AZD8683 is an investigational small molecule being developed by AstraZeneca for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It has been studied in healthy volunteers and in patients with COPD, with clinical trials assessing its safety, tolerability, pharmacokinetics, and pharmacodynamics.
AZD8683 is being developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker AZN. The company has conducted clinical trials of AZD8683 in the United States, Poland, and the United Kingdom.
AZD8683 has completed Phase 1 and Phase 2 clinical trials. The Phase 2 study evaluated the effect of AZD8683 in patients with Chronic Obstructive Pulmonary Disease (COPD). All trials listed for AZD8683 are completed, and the drug remains investigational, not approved by regulatory authorities.
AZD8683 has been studied in three completed clinical trials: NCT00979849, a Phase 1 single ascending dose study in healthy volunteers in the United States; NCT01205269, a Phase 2 study in COPD patients in Poland; and NCT01419600, a Phase 1 study of single ascending doses of inhaled AZD8683 in healthy volunteers in the United Kingdom.
No alternative names for AZD8683 have been reported. The drug is identified solely by its code name AZD8683 in clinical trial registries and scientific literature. It is not known to be marketed under any other brand name.